Dexcom‘s (Nasdaq:DXCM) C-suite is seeing another of its members take on multiple roles. Its chief financial officer will now also serve as chief operating officer. Jereme Sylvain joined the diabetes tech company in 2018, and has been its CFO and executive VP since 2021. His new COO hat will add oversight of Dexcom’s global operations […]
Dexcom
Dexcom adds former Stryker CFO to board
CGM maker Dexcom (Nasdaq: DXCM) is adding the former CFO of orthopedic and surgical device giant Stryker to its board of directors. Glenn Boehnlein’s appointment was in effect yesterday — the day of the announcement. Boehnlein’s addition expands the size of Dexcom’s board to 13. Boehnlein retired from Stryker last year after 22 years with […]
The 10 largest diabetes tech companies in the world in 2026
Over the last year, a lot has changed in the diabetes technology space. Does that ring true for the rankings of the space’s largest companies? Within the last 12 months, we’ve seen one of the industry’s biggest players separate from its parent company. We’ve also seen significant regulatory milestones, product launches and unveilings of next-generation […]
Diabetes Technology Innovations Special Report — 2026
Last year, MassDevice and Drug Delivery Business News rolled out the first edition of their Diabetes Technology Innovations Special Report. Now, we have the second edition available for free download, providing an in-depth overview of where the diabetes industry currently stands after another year of innovation and growth. The diabetes tech industry delivers some of the most advanced combinations of […]
Dexcom Q2 results beat expectations, lead to increased sales outlook
Dexcom (Nasdaq:DXCM) today reported second-quarter results that came in ahead of the consensus Wall Street forecast. Shares of DXCM rose 2% to $76.02 apiece after the market closed today. The San Diego-based continuous glucose monitor (CGM) maker reported profits of $249.1 million. That equals 64¢ per share on sales of $1.31 billion for the three […]
FDA selects Dexcom for new digital health device pilot
The FDA announced today that it selected Dexcom (Nasdaq:DXCM) as the first manufacturer for a new digital health pilot. Dexcom joins the Technology-Enabled Meaningful Patient Outcomes (TEMPO) for Digital Health Devices Pilot. It intends to provide a device for use in delivering care expected to be covered by the Centers for Medicare & Medicaid Services […]
Dexcom picks up Health Canada nod for G7 15 Day
Dexcom (Nasdaq:DXCM) announced today that Health Canada authorized its G7 15 Day continuous glucose monitor (CGM) system. Health Canada approval covers people 18 years and older living with diabetes. It brings the G7 15 Day, its longest-lasting wearable sensor, to Canada, with the system already possessing FDA clearance. G7 15 Day delivers several features of […]
ViCentra Kaleido with G7, DBLG2 algorithm now available in Germany
Diabeloop announced today that its DBLG2 automated insulin delivery algorithm is now open for prescription with Dexcom G7 and ViCentra Kaleido. The companies now offer their integrated automated insulin delivery system in Germany, with availability to come in the Netherlands soon. Their updated system combines the company’s Kaleido patch pump with Diabeloop’s DBLG2 algorithm and the Dexcom G7 continuous glucose […]
Dexcom launches enhanced Stelo app
Dexcom (Nadsaq:DXCM) today announced the launch of its fully reimagined Stelo over-the-counter (OTC) sensor app experience. San Diego-based Dexcom plans to formally begin the new app rollout in July for Apple iPhone and Android users in the U.S. The company At ADA 2026, Dexcom said it planned to offer select users the opportunity for early […]
FDA clears Dexcom Stelo over-the-counter CGM for children
Dexcom (Nadsaq:DXCM) has received FDA clearance for its Stelo over-the-counter (OTC) continuous glucose monitor (CGM) for children. The FDA said in a news release that it cleared Stelo for people two years of age and older who do not use insulin. It became the first OTC CGM system granted clearance in March 2024, initially getting […]
